File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Antiphospholipid antibodies in lupus nephritis – a single centre experience

TitleAntiphospholipid antibodies in lupus nephritis – a single centre experience
Authors
Issue Date2018
PublisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/
Citation
55th European Renal Association & European Dialysis and Transplant Association Congress (ERA-EDTA 2018), Copenhagen, Denmark, 24-27 May 2018. In Nephrology Dialysis Transplantation, 2018, v. 33 n. Suppl. 1, p. i322 How to Cite?
AbstractINTRODUCTION AND AIMS: The clinical significance of antiphospholipid antibodies (APA) in lupus nephritis (LN) remains to be defined. METHODS: We retrospectively reviewed 149 LN patients who were followed at the SLE clinic of Queen Mary Hospital, Hong Kong during 2000-2017, and compared the long-term clinical outcomes between patients seropositive or seronegative for APA. RESULTS: 53 patients (35.6%) were seropositive for APA and 96 (64.4%) were seronegative, and were followed for 150.3±63.4 and 158.9±59.8 months respectively. The sero-prevalence rates for anti-cardiolipin IgM, anti-cardiolipin IgG, anti-β2 glycoprotein I and lupus anticoagulant were 18.8%, 18.1%, 10.7% and 8.1% respectively. APA-seropositive patients showed inferior long-term patient survival (91% and 85% at 10- and 15-year respectively, compared with 99% and 95% in APA-seronegative patients, p=0.043, Figure 1, A). Six APA-seropositive patients died, four because of thrombotic events and two because of bleeding complications related to anti-coagulation. Three APA-seronegative patients died, two due to pneumonia and one due to bowel ischemia. APA-seropositive LN patients also showed more rapid decline in eGFR (-1.44 mL/min/year, compared with -0.38 mL/min/year in APA-seronegative patients, p=0.027) and inferior long-term renal survival (82% and 74% at 10- and 15-year respectively, compared with 91% and 87% in APA-seronegative patients, p=0.034; Figure 1, B). The APA-seropositive group also had higher incidence of thrombotic events and miscarriage (32.1% and 13.2%, compared with 16.7% and 2.1% in the APA-seronegative group respectively, p=0.030 and 0.006). CONCLUSIONS: APA-seropositivity was associated with inferior long-term patient and renal survival, and more frequent thrombotic events and miscarriage in LN patients.
DescriptionSession: Free Communication Session: Glomerulonephritis 1 - no. SaO017
Persistent Identifierhttp://hdl.handle.net/10722/260767
ISSN
2023 Impact Factor: 4.8
2023 SCImago Journal Rankings: 1.414

 

DC FieldValueLanguage
dc.contributor.authorYap, YHD-
dc.contributor.authorThong, KM-
dc.contributor.authorYung, S-
dc.contributor.authorTang, CSO-
dc.contributor.authorMa, BM-
dc.contributor.authorChan, DTM-
dc.date.accessioned2018-09-14T08:47:03Z-
dc.date.available2018-09-14T08:47:03Z-
dc.date.issued2018-
dc.identifier.citation55th European Renal Association & European Dialysis and Transplant Association Congress (ERA-EDTA 2018), Copenhagen, Denmark, 24-27 May 2018. In Nephrology Dialysis Transplantation, 2018, v. 33 n. Suppl. 1, p. i322-
dc.identifier.issn0931-0509-
dc.identifier.urihttp://hdl.handle.net/10722/260767-
dc.descriptionSession: Free Communication Session: Glomerulonephritis 1 - no. SaO017-
dc.description.abstractINTRODUCTION AND AIMS: The clinical significance of antiphospholipid antibodies (APA) in lupus nephritis (LN) remains to be defined. METHODS: We retrospectively reviewed 149 LN patients who were followed at the SLE clinic of Queen Mary Hospital, Hong Kong during 2000-2017, and compared the long-term clinical outcomes between patients seropositive or seronegative for APA. RESULTS: 53 patients (35.6%) were seropositive for APA and 96 (64.4%) were seronegative, and were followed for 150.3±63.4 and 158.9±59.8 months respectively. The sero-prevalence rates for anti-cardiolipin IgM, anti-cardiolipin IgG, anti-β2 glycoprotein I and lupus anticoagulant were 18.8%, 18.1%, 10.7% and 8.1% respectively. APA-seropositive patients showed inferior long-term patient survival (91% and 85% at 10- and 15-year respectively, compared with 99% and 95% in APA-seronegative patients, p=0.043, Figure 1, A). Six APA-seropositive patients died, four because of thrombotic events and two because of bleeding complications related to anti-coagulation. Three APA-seronegative patients died, two due to pneumonia and one due to bowel ischemia. APA-seropositive LN patients also showed more rapid decline in eGFR (-1.44 mL/min/year, compared with -0.38 mL/min/year in APA-seronegative patients, p=0.027) and inferior long-term renal survival (82% and 74% at 10- and 15-year respectively, compared with 91% and 87% in APA-seronegative patients, p=0.034; Figure 1, B). The APA-seropositive group also had higher incidence of thrombotic events and miscarriage (32.1% and 13.2%, compared with 16.7% and 2.1% in the APA-seronegative group respectively, p=0.030 and 0.006). CONCLUSIONS: APA-seropositivity was associated with inferior long-term patient and renal survival, and more frequent thrombotic events and miscarriage in LN patients.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/-
dc.relation.ispartofNephrology Dialysis Transplantation-
dc.relation.ispartofEuropean Renal Association & European Dialysis and Transplant Association (ERA-EDTA) Congress, 2018-
dc.titleAntiphospholipid antibodies in lupus nephritis – a single centre experience-
dc.typeConference_Paper-
dc.identifier.emailYap, YHD: desmondy@hku.hk-
dc.identifier.emailTang, CSO: csotang@hkucc.hku.hk-
dc.identifier.emailChan, DTM: dtmchan@hkucc.hku.hk-
dc.identifier.authorityYap, YHD=rp01607-
dc.identifier.authorityChan, DTM=rp00394-
dc.identifier.doi10.1093/ndt/gfy104.SaO017-
dc.identifier.hkuros290842-
dc.identifier.volume33-
dc.identifier.issueSuppl. 1-
dc.identifier.spagei322-
dc.identifier.epagei322-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0931-0509-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats